Mycophenolate Mofetil in ILD with NSIP Pattern and CKD

Efficacy in ILD with NSIP Pattern

The American College of Rheumatology (ACR) and American College of Chest Physicians (CHEST) conditionally recommend mycophenolate mofetil (MMF) as a first-line treatment option for systemic autoimmune rheumatic disease-associated ILD (SARD-ILD) in patients with chronic kidney disease (CKD) 1, 2

Baseline and periodic liver function tests should be performed to monitor for hepatotoxicity in patients with CKD taking MMF, as recommended by the American College of Rheumatology 1

Mycophenolate mofetil (MMF) has a more favorable side effect profile compared to cyclophosphamide and does not cause significant nephrotoxicity, making it suitable for patients with CKD, according to the American College of Rheumatology 1
MMF allows for reduction or discontinuation of prednisone without worsening of symptoms or objective progression of disease in patients with autoimmune-related ILD, although the strength of evidence is not provided 3

Regular monitoring of blood counts is essential for patients with CKD taking MMF, with more frequent monitoring recommended, as suggested by the American College of Rheumatology 1

Initial assessment should include confirmation of NSIP pattern through HRCT and/or lung biopsy, as recommended by the American Journal of Respiratory and Critical Care Medicine 4
Baseline pulmonary function tests (PFTs) and oxygen requirements should be evaluated, as suggested by the American College of Chest Physicians 5
For patients with severe CKD or ESRD, a lower dose of MMF not exceeding 1g daily is recommended, with closer monitoring for side effects, although the strength of evidence is not provided 3

The American College of Rheumatology recommends starting mycophenolate mofetil at 500 mg twice daily and gradually increasing to a target dose of 1,000-1,500 mg twice daily, with dose escalation occurring every 2-3 weeks based on tolerability and laboratory monitoring 6
For mycophenolic acid formulation, the initial dose is 360 mg orally twice daily, with a target dose of 720-1,080 mg twice daily 6
In systemic sclerosis-ILD, the standard dose is 2-3 grams per day of mycophenolate mofetil, as supported by clinical trials 7
Most clinical trials supporting MMF efficacy in SARD-ILD used the 2-3 gram daily dosing range, with a strength of evidence based on multiple studies 8, 9

The dose should be increased every 2-3 weeks after checking laboratory parameters, specifically CBC with differential and comprehensive metabolic panel, to minimize the risk of adverse effects 6
Laboratory monitoring should be performed 2-3 weeks after starting therapy and after each dose increase, with a common escalation pathway of 500 mg twice daily → 750 mg twice daily → 1,000 mg twice daily → 1,500 mg twice daily 6
CBC with differential and CMP should be monitored at baseline, then 2-3 weeks after starting and after each dose increase, with annual full body skin examination by dermatologist due to increased malignancy risk 6

Long-term maintenance therapy is typically required, as discontinuation may lead to disease progression, with a minimum treatment duration of 24 months based on clinical trials 8
The American College of Rheumatology conditionally recommends against upfront combination therapy of MMF with nintedanib or pirfenidone, with combination therapy only considered if ILD progresses despite MMF monotherapy 8, 9, 10

The American College of Rheumatology conditionally recommends mycophenolate as a first-line treatment option for interstitial lung disease associated with systemic autoimmune rheumatic diseases, including systemic sclerosis, rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and mixed connective tissue disease 11, 12
The American College of Rheumatology guideline panel positions mycophenolate as the "preferred" first-line option across all SARD-ILD subtypes, based on head-to-head voting, due to its similar efficacy to cyclophosphamide but with a more favorable adverse effect profile 11, 12

Mycophenolate produces similar outcomes as cyclophosphamide regarding forced vital capacity stabilization and improvement in patients with systemic sclerosis-ILD 11
Mycophenolate is conditionally recommended as one of several first-line options for rapidly progressive ILD, alongside rituximab, cyclophosphamide, IVIG, calcineurin inhibitors, and JAK inhibitors, with combination therapy preferred over monotherapy 12

Mycophenolate is safe and well-tolerated in CTD-ILD patients, with most side effects resolving with dose reduction, and has a favorable tolerability profile compared to cyclophosphamide, with no significant nephrotoxicity 11

For patients with continued progression despite optimal medical management, consider early lung transplant referral, and switch to or add rituximab, nintedanib, or cyclophosphamide as second-line options 12
In systemic sclerosis-ILD, mycophenolate is preferred over azathioprine due to stronger evidence of effectiveness, and glucocorticoids are strongly recommended against as first-line therapy due to scleroderma renal crisis risk 11, 12